492 related articles for article (PubMed ID: 26661498)
1. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris.
Schmidt T; Willenborg S; Hünig T; Deeg CA; Sonderstrup G; Hertl M; Eming R
Exp Dermatol; 2016 Apr; 25(4):293-8. PubMed ID: 26661498
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.
Eming R; Hennerici T; Bäcklund J; Feliciani C; Visconti KC; Willenborg S; Wohde J; Holmdahl R; Sønderstrup G; Hertl M
J Immunol; 2014 Nov; 193(9):4391-9. PubMed ID: 25252957
[TBL] [Abstract][Full Text] [Related]
3. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles.
Veldman C; Stauber A; Wassmuth R; Uter W; Schuler G; Hertl M
J Immunol; 2003 Jan; 170(1):635-42. PubMed ID: 12496453
[TBL] [Abstract][Full Text] [Related]
4. Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice.
Hofrichter M; Dworschak J; Emtenani S; Langenhan J; Weiß F; Komorowski L; Zillikens D; Stöcker W; Probst C; Schmidt E; Goletz S
Front Immunol; 2018; 9():1935. PubMed ID: 30233569
[TBL] [Abstract][Full Text] [Related]
5. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.
Pollmann R; Schmidt T; Eming R; Hertl M
Clin Rev Allergy Immunol; 2018 Feb; 54(1):1-25. PubMed ID: 29313220
[TBL] [Abstract][Full Text] [Related]
6. Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris.
Didona D; Scarsella L; Hudemann C; Volkmann K; Zimmer CL; Beckert B; Tikkanen R; Korff V; Kühn K; Wienzek-Lischka S; Bein G; Di Zenzo G; Böhme J; Cunha T; Solimani F; Pieper J; Juratli HA; Göbel M; Schmidt T; Borradori L; Yazdi AS; Sitaru C; Garn H; Eming R; Fleischer S; Hertl M
J Invest Dermatol; 2024 Feb; 144(2):263-272.e8. PubMed ID: 37717934
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris.
Hertl M; Riechers R
J Dermatol; 1999 Nov; 26(11):748-52. PubMed ID: 10635617
[TBL] [Abstract][Full Text] [Related]
8. Human Desmocollin 3‒Specific IgG Antibodies Are Pathogenic in a Humanized HLA Class II Transgenic Mouse Model of Pemphigus.
Hudemann C; Maglie R; Llamazares-Prada M; Beckert B; Didona D; Tikkanen R; Schmitt T; Hashimoto T; Waschke J; Hertl M; Eming R
J Invest Dermatol; 2022 Mar; 142(3 Pt B):915-923.e3. PubMed ID: 34265330
[TBL] [Abstract][Full Text] [Related]
9. [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris].
Zhong S; Qiu YF; Han BB; Zhao JY; Zhu XJ; Chen XX
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 43(3):414-5. PubMed ID: 21681274
[TBL] [Abstract][Full Text] [Related]
10. Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris.
Yokoyama T; Matsuda S; Takae Y; Wada N; Nishikawa T; Amagai M; Koyasu S
Int Immunol; 2011 Jun; 23(6):365-73. PubMed ID: 21525154
[TBL] [Abstract][Full Text] [Related]
11. Mucosal pemphigus vulgaris anti-Dsg3 IgG is pathogenic to the oral mucosa of humanized Dsg3 mice.
Culton DA; McCray SK; Park M; Roberts JC; Li N; Zedek DC; Anhalt GJ; Cowley DO; Liu Z; Diaz LA
J Invest Dermatol; 2015 Jun; 135(6):1590-1597. PubMed ID: 25695683
[TBL] [Abstract][Full Text] [Related]
12. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
[TBL] [Abstract][Full Text] [Related]
13. The imbalance of Th17 and regulatory T cells in pemphigus patients.
Xu RC; Zhu HQ; Li WP; Zhao XQ; Yuan HJ; Zheng J; Pan M
Eur J Dermatol; 2013; 23(6):795-802. PubMed ID: 24192290
[TBL] [Abstract][Full Text] [Related]
14. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1.
Lin MS; Swartz SJ; Lopez A; Ding X; Fairley JA; Diaz LA
J Invest Dermatol; 1997 Dec; 109(6):734-7. PubMed ID: 9406813
[TBL] [Abstract][Full Text] [Related]
15. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model.
Aoki-Ota M; Kinoshita M; Ota T; Tsunoda K; Iwasaki T; Tanaka S; Koyasu S; Nishikawa T; Amagai M
J Invest Dermatol; 2006 Jan; 126(1):105-13. PubMed ID: 16417225
[TBL] [Abstract][Full Text] [Related]
16. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris.
Veldman C; Höhne A; Dieckmann D; Schuler G; Hertl M
J Immunol; 2004 May; 172(10):6468-75. PubMed ID: 15128839
[TBL] [Abstract][Full Text] [Related]
17. IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris.
Müller R; Svoboda V; Wenzel E; Gebert S; Hunzelmann N; Müller HH; Hertl M
Exp Dermatol; 2006 Aug; 15(8):606-14. PubMed ID: 16842599
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions.
Nguyen VT; Ndoye A; Shultz LD; Pittelkow MR; Grando SA
J Clin Invest; 2000 Dec; 106(12):1467-79. PubMed ID: 11120754
[TBL] [Abstract][Full Text] [Related]
19. HLA-DRB1 polymorphisms and autoimmune responses to desmogleins in Japanese patients with pemphigus.
Miyagawa S; Amagai M; Niizeki H; Yamashina Y; Kaneshige T; Nishikawa T; Shirai T; Inoko H
Tissue Antigens; 1999 Oct; 54(4):333-40. PubMed ID: 10551416
[TBL] [Abstract][Full Text] [Related]
20. Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation.
Kawasaki H; Tsunoda K; Hata T; Ishii K; Yamada T; Amagai M
J Invest Dermatol; 2006 Dec; 126(12):2621-30. PubMed ID: 16841036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
